R2 Innovations
Biotechnology, 8100 S Akron Street, CENTENNIAL, Colorado, 80112, United States, 1-10 Employees
Phone Number: 30********
Who is R2 INNOVATIONS
ABOUT R2 INNOVATIONS THE COMPANY R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998 a privately owned, Colorado Limited Liability Company. R2 has arrang...
Read More
-
Headquarters: 8100 S Akron Street, CENTENNIAL, Colorado, 80112, United States
-
Date Founded: 1998
-
Employees: 1-10
-
Revenue: Under $1 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from R2 INNOVATIONS
R2 Innovations Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding R2 Innovations
Answer: R2 Innovations's headquarters are located at 8100 S Akron Street, CENTENNIAL, Colorado, 80112, United States
Answer: R2 Innovations's phone number is 30********
Answer: R2 Innovations's official website is https://r2innovations.com
Answer: R2 Innovations's revenue is Under $1 Million
Answer: R2 Innovations's SIC: 2836
Answer: R2 Innovations's NAICS: 541714
Answer: R2 Innovations has 1-10 employees
Answer: R2 Innovations is in Biotechnology
Answer: R2 Innovations contact info: Phone number: 30******** Website: https://r2innovations.com
Answer: ABOUT R2 INNOVATIONS THE COMPANY R2 Innovations, LLC was founded by Robert L. Senter and Robert E. Matuszewski in 1998 a privately owned, Colorado Limited Liability Company. R2 has arranged equity partnerships with industry leaders in the field of drying and micronizing microparticles and nanoparticles into dry powder aerosols for the purpose of inhalation therapies, targeting the treatment of respiratory diseases, including asthma, emphysema and COPD. In addition to dry powder formulations targeting pulmonary and respiratory disorders; US patent pending processes, research and studies are underway to convert CBD, cannabidiol and other cannabis derived, extracted oils into pharmaceutical grade, fine powder formulations using R2s pressurized, metered dose inhaler (pMDI) and R2's dry powder inhaler (DPI) technologies directed at treating stress, post traumatic stress disorders (PTSD), anti-inflammatory pain relief and insomnia. R2 MISSION R2s Mission is to be recognized as a global leader in the development and manufacturing of natural medicines to treat specific, targeted ailments and diseases. At R2 we are devoted to delivering alternative medical treatments to solve ongoing medical problems and support important advancements in medical science. R2 OBJECTIVE R2s objective is to challenge the use of; fluticasone propionate/salmeterol xinafoate, budesonide/formoterol, albuterol/salbutamol, budesonide, fluticasone and formoterol fumarate as the preferred corticosteroid medical treatments in existing metered dose inhalers eliminating adverse side effects, and the threat of death with overdosing for asthmatic, COPD and Emphysema patients. R2 VISION R2's Vision is to lead the global marketplace in advanced alternative medicines with an emphasis on respiratory therapies, supported by clinical research, double blind studies and independent lab testing.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month